Jane Street
APGE icon

Jane Street’s Apogee Therapeutics APGE Stock Holding History

Jane Street’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.7M Buy
55,800
+50,100
+879% +$3.64M ﹤0.01% 3618
2025
Q4 		$430K Sell
5,700
-29,800
-84% -$1.88M ﹤0.01% 8042
2025
Q3 		$1.41M Sell
35,500
-300
-0.8% -$11.5K ﹤0.01% 5592
2025
Q2 		$1.55M Buy
35,800
+25,900
+262% +$985K ﹤0.01% 4828
2025
Q1 		$370K Sell
9,900
-5,300
-35% -$205K ﹤0.01% 7450
2024
Q4 		$689K Sell
15,200
-34,800
-70% -$1.77M ﹤0.01% 6100
2024
Q3 		$2.94M Buy
+50,000
New +$2.4M ﹤0.01% 3752

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jane Street's APGE Position: Q1 2026 in Review

Jane Street sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 12,192 shares — an estimated $885K sold.

Jane Street first reported a position in APGE in Q3 2023 and held it in 10 quarters. The position peaked at $3.73M in Q1 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Jane Street reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 12,192 Apogee Therapeutics shares in Q1 2026, an estimated $885K.
  • Jane Street first reported a position in Apogee Therapeutics in Q3 2023 and held it in 10 quarters.
  • Jane Street's Apogee Therapeutics position peaked at $3.73M in Q1 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.